Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Angioli

Showing results (201-210 of 247) with videos related to

Pageof 25
Sort By:
Eclinicalmedicine|June 14, 2024
Tranexamic acid versus oxytocin prophylaxis in reducing post-partum blood loss, in low-risk pregnant women: TRANOXY STUDY, a phase III randomized clinical trialAntonio Ragusa, Fernando Ficarola, Amerigo Ferrari, et al.
Journal of Personalized Medicine|January 22, 2024
The Utility of CO<sub>2</sub> Laser Treatment of Pelvic Symptoms in Women with Previous Perineal Trauma during DeliveryMaurizio Filippini, Roberto Angioli, Daniela Luvero, et al.
Minerva Ginecologica|September 4, 2020
Sentinel lymph node in cervical cancer: a literature review on the use of conservative surgery techniquesFrancesco Plotti, Giuseppe Messina, Corrado Terranova, et al.
Journal of Clinical Medicine|September 13, 2025
The Role of Deep Neuromuscular Blockade and Sugammadex in Laparoscopic Hysterectomy: A Randomized Controlled TrialCorrado Terranova, Lorenzo Schiavoni, Francesco Plotti, et al.
International Journal of Molecular Sciences|May 23, 2017
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future PerspectivesSalvatore Giovanni Vitale, Antonio Simone Laganà, Stella Capriglione, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 14, 2012
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomasFederica Guzzo, Stefania Bellone, Natalia Buza, et al.
Gynecologic Oncology|January 10, 2020
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II studyMolly Brewer, Roberto Angioli, Giovani Scambia, et al.
Molecular Cancer Therapeutics|September 4, 2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In VivoSalvatore Lopez, Emiliano Cocco, Jonathan Black, et al.
Proteomics|October 15, 2014
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapyMaria Isabella Sereni, Elisa Baldelli, Guido Gambara, et al.
Acta Bio-Medica : Atenei Parmensis|November 10, 2020
Complications related to in vitro reproductive techniques support the implementation of natural procreative technologiesAysha Karim Kiani, Stefano Paolacci, Pietro Scanzano, et al.
Pageof 25

Showing results (201-210 of 247) with videos related to

Sort By:
Pageof 25
Eclinicalmedicine|June 14, 2024
Tranexamic acid versus oxytocin prophylaxis in reducing post-partum blood loss, in low-risk pregnant women: TRANOXY STUDY, a phase III randomized clinical trialAntonio Ragusa, Fernando Ficarola, Amerigo Ferrari, et al.
Journal of Personalized Medicine|January 22, 2024
The Utility of CO<sub>2</sub> Laser Treatment of Pelvic Symptoms in Women with Previous Perineal Trauma during DeliveryMaurizio Filippini, Roberto Angioli, Daniela Luvero, et al.
Minerva Ginecologica|September 4, 2020
Sentinel lymph node in cervical cancer: a literature review on the use of conservative surgery techniquesFrancesco Plotti, Giuseppe Messina, Corrado Terranova, et al.
Journal of Clinical Medicine|September 13, 2025
The Role of Deep Neuromuscular Blockade and Sugammadex in Laparoscopic Hysterectomy: A Randomized Controlled TrialCorrado Terranova, Lorenzo Schiavoni, Francesco Plotti, et al.
International Journal of Molecular Sciences|May 23, 2017
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future PerspectivesSalvatore Giovanni Vitale, Antonio Simone Laganà, Stella Capriglione, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 14, 2012
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomasFederica Guzzo, Stefania Bellone, Natalia Buza, et al.
Gynecologic Oncology|January 10, 2020
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II studyMolly Brewer, Roberto Angioli, Giovani Scambia, et al.
Molecular Cancer Therapeutics|September 4, 2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In VivoSalvatore Lopez, Emiliano Cocco, Jonathan Black, et al.
Proteomics|October 15, 2014
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapyMaria Isabella Sereni, Elisa Baldelli, Guido Gambara, et al.
Acta Bio-Medica : Atenei Parmensis|November 10, 2020
Complications related to in vitro reproductive techniques support the implementation of natural procreative technologiesAysha Karim Kiani, Stefano Paolacci, Pietro Scanzano, et al.
Pageof 25